3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Vomiting
1
Uterine Cervical Neoplasms
1
Postoperative Nausea and Vomiting
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Interventions
pembrolizumab
19
Docetaxel
9
atezolizumab
8
Cetuximab
8
Nivolumab
7
cemiplimab
6
Ipilimumab
4
Immune Checkpoint Inhibitors
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
palbociclib
3
fludarabine
3
durvalumab
3
avelumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Fulvestrant
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
Bortezomib
3
Blood Specimen Collection
3
seribantumab
2
selpercatinib
2
pazopanib
2
motexafin gadolinium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Diphenhydramine
×
Breast
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled